AbbVie to acquire Botox maker Allergan for $63bn | Financial Times
Cash and stock offer marks latest blockbuster deal in healthcare sector
✒ Judging from AbbVie’s 15% fall of share price, AbbVie’s shareholders apparently are not impressed by the 45 per cent premium it is paying.